Status:
COMPLETED
Extracranial Stereotactic Radiosurgery in Treating Patients With Solid Tumors
Lead Sponsor:
Wake Forest University Health Sciences
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Unspecified Adult Solid Tumor, Protocol Specific
Eligibility:
All Genders
18-120 years
Phase:
PHASE1
PHASE2
Brief Summary
RATIONALE: Extracranial stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This phase I/II trial is studying the side effects ...
Detailed Description
OBJECTIVES: Primary * Establish the maximum tolerated dose (MTD) of extracranial stereotactic radiosurgery in patients with isolated tumors. (Phase I) * Determine the minimum dose required for local...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Presence of well-circumscribed tumor on contrast-enhanced CT scan or MRI
- Maximum diameter of 6 cm
- PATIENT CHARACTERISTICS:
- Life expectancy ≥ 3 months
- Not pregnant
- Fertile patients must use effective contraception
- Negative pregnancy test
- Must be able to tolerate CT scan or MRI contrast
- PRIOR CONCURRENT THERAPY:
- At least 3 weeks since prior chemotherapy or immunotherapy
- No prior treatment on this study
- No chemotherapy or immunotherapy during and for 4 weeks after completion of study treatment
- No concurrent external-beam radiotherapy overlapping with the radiosurgically-treated volume (including low-dose regions)
Exclusion
Key Trial Info
Start Date :
June 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2009
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00311597
Start Date
June 1 2002
End Date
March 1 2009
Last Update
March 14 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wake Forest University Comprehensive Cancer Center
Winston-Salem, North Carolina, United States, 27157-1096